Patients and treatment
ONCOLOGY, SOLID TUMOR
Between July 23, 2018, and April 27, 2020, 136 patients were randomized to receive pamiparib (Patient flow. ITT, intent‐to‐treat.Patient demographics and baseline characteristics.Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.“Not reported” and “Unknown” include patients from France who did not consent to the collection of race information.Geographic regions are presented as per the groupings used as stratification factors during randomization.No patients were enrolled in South Korea.Solid tumor stage at screening.At data cutoff (June 18, 2020), median follow‐up duration was 8.0 months (pamiparib arm, 7.9 months; placebo arm, 8.0 months). Seventy patients (51.5%) remained in the study, and 23 (16.9%) remained on treatment (Figure 